Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 315 treatment comparisons .

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
NCT04425915
COPLA-II trial
Bajpai M, BMJ Open, 2022
Full text
Commentary
Commentary
No specific funding

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. N=400
Some concerns
Details

Full description

New
NCT04438980 ; EudraCT 2020-001827-15
CORTIVID
Les I, Front Med , 2022
Full text
Commentary
Commentary
Public/non profit

Intravenous Methylprednisolone pulse

Placebo

RCT Patients with confirmed COVID-19 (moderate) admitted to 2 centers in Spain. N=72
Low
Details

Full description

New
NCT04405310
Fernandez-Sanchez V, Research Square, 2022
Full text
Commentary
Commentary
Public/non profit

Convalescent plasma

Placebo

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to two centers in Mexico N=43
Some concerns
Details

Full description

New
NCT04505774
ACTIV-4a
Berger JS, JAMA, 2022
Full text
Commentary
Commentary
Public/non profit

Therapeutic anticoagulant + P2Y12 Inhibitor

Therapeutic anticoagulant

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 60 centers in Brazil, Italy, Spain and USA. N=562
Some concerns
Details

Full description

New
CTRI/2020/07/026835
Nair PR, Respir Care, 2021
Full text
Commentary
Public/non profit

Noninvasive ventilation

High flow nasal cannula

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in India. N=109
Some concerns
Details

Full description

NCT04351243
BREATHE
Criner GJ , Am J Respir Crit Care Med, 2022
Full text
Commentary
Private

Gimsilumab

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 21 centers in the USA. N=227
Some concerns
Details

Full description

NCT04673162 ; EudraCT 2020-004323-16
Salvarani C, Eur Respir J, 2022
Full text
Commentary
No specific funding

Methylprednisolone

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 19 centers in Italy. N=304
Low
Details

Full description

IRCT20200506047323N3
Hassaniazad M, J Med Virol, 2022
Full text
Commentary
Public/non profit

Favipiravir

Lopinavir + Ritonavir

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=66
Some concerns
Details

Full description

IRCT20151227025726N14
Tabarsi P, Iran J Pharm Res, 2021
Full text
Commentary
Commentary
Public/non profit

Favipiravir

Lopinavir + Ritonavir

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=62
Some concerns
Details

Full description

N/A
Manomaipiboon A, Research square, 2022
Full text
Commentary
Commentary
Public/non profit

Ivermectin

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in Thailand. N=74
Some concerns
Details

Full description